{
    "physical_examinations": [
        {
            "date": "Not specified",
            "vital_signs": "Not specified",
            "relevant_findings": "At initial presentation at 4 months of age, laboratory analyses revealed elevated levels of inflammation markers (C-reactive protein), erythrocyte sedimentation rate, and markedly elevated total serum alkaline phosphatase (TSAP) levels (1248 U/L; upper norm, 341 U/L).",
            "changes_over_time": "Not specified"
        },
        {
            "date": "Not specified",
            "vital_signs": "Not specified",
            "relevant_findings": "Developed severe coxa vara with Shepherd’s crook deformity bilaterally, bowing deformities, and a pathological fracture of the left tibia during treatment. Suffered from frequent bone pain and sensorineural hearing loss.",
            "changes_over_time": "Despite reduction in TSAP levels with bisphosphonate treatment, bone deformities were progressive, and pain returned after initial relief following treatment."
        },
        {
            "date": "Not specified",
            "vital_signs": "Serum calcium: 2.08 mmol/L (normal, 2.15–2.45); ionized calcium: 0.87 mmol/L (lower norm, 1.1)",
            "relevant_findings": "Severe hypocalcemia developed 5 hours after the first denosumab injection, requiring hospitalization and IV calcium supplementation for 3 days.",
            "changes_over_time": "Post-denosumab, calcium requirements were elevated initially but decreased 17 days later as stabilization occurred."
        },
        {
            "date": "Not specified",
            "vital_signs": "Serum calcium: 4.07 mmol/L (normal range, 2.15–2.45)",
            "relevant_findings": "Marked hypercalcemia observed 7 weeks after second dose of denosumab, with symptoms of polyuria, nausea, and constipation.",
            "changes_over_time": "Hypercalcemia developed rapidly only 4 days after a normal calcium reading, indicating a severe fluctuation."
        }
    ]
}